Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade, reflecting a changing investor sentiment amid mixed market signals. Despite a recent 4.01% dip in its share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more attractive entry point compared to its historical highs and peer group averages.

Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Surging past its previous peaks, Novelix Pharmaceuticals Ltd touched a fresh 52-week high of Rs 92 on 16 Jun 2026, marking a remarkable rally that has seen the stock gain nearly 197% over the past year, vastly outperforming the Sensex’s decline of 6.37% during the same period.

Novelix Pharmaceuticals Ltd, a micro-cap player in the retailing sector, achieved a significant milestone on 16 Jun 2026 as its stock price touched an all-time high of Rs.92. This marks a remarkable phase in the company’s market journey, reflecting sustained gains and strong performance metrics over multiple time horizons.

Surging to an all-time high of Rs 87.9 on 15 Jun 2026, Novelix Pharmaceuticals Ltd has demonstrated remarkable price momentum, extending gains for nine consecutive sessions and delivering a 63.28% return over this period. This rally unfolds amid a broadly positive market backdrop, with the Sensex trading near its recent peaks.

Novelix Pharmaceuticals Ltd has reached a significant milestone by touching an all-time high price of Rs.87.90 on 15 Jun 2026, marking a remarkable phase in the company’s stock performance within the retailing sector.

Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Surging past its previous peaks, Novelix Pharmaceuticals Ltd reached a fresh 52-week high of Rs 84.7 on 12 Jun 2026, propelled by a confluence of strong technical signals and sustained price momentum over the past eight trading sessions.

Novelix Pharmaceuticals Ltd has reached a significant milestone by touching an all-time high price of Rs.84.7 on 12 June 2026, marking a remarkable phase in the company’s market journey. This achievement reflects sustained gains and strong performance metrics across multiple timeframes.

With a remarkable 48.09% gain over the past five trading sessions, Novelix Pharmaceuticals Ltd surged to a fresh 52-week high of Rs 78.94 on 09 Jun 2026, showcasing robust momentum driven by a confluence of bullish technical indicators.

Novelix Pharmaceuticals Ltd has reached a significant milestone by touching its all-time high price of Rs. 71.60 on 9 June 2026, marking a remarkable achievement in the company’s market journey within the retailing sector.

Surging to an intraday peak of Rs 71 on 8 Jun 2026, Novelix Pharmaceuticals Ltd has marked a significant milestone by hitting a fresh 52-week high. This breakout comes amid a sustained four-day rally that has propelled the stock up by 32.9%, underscoring robust price momentum despite a broadly subdued market backdrop.

Novelix Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting a significant change in price attractiveness. This article analyses the recent valuation metrics, compares them with peer averages and historical benchmarks, and assesses the implications for investors amid the company’s strong market performance.

Novelix Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade, reflecting a more attractive price point for investors. This change comes amid a mixed performance backdrop and evolving market dynamics within the retailing sector.

Novelix Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 01 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.